Anti-vascular agent Combretastatin A-4-P modulates hypoxia inducible factor-1 and gene expression

BMC Cancer

Volumn 6, Issue , 2006, Pages

  Dachs, Gabi U ^a,b   Steele, Andrew J ^b   Coralli, Claudia ^b   Kanthou, Chryso ^b,c   Brooks, Andrew C ^b   Gunningham, Sarah P ^a   Curie, Margaret J ^a   Watson, Ally I ^a   Robinson, Bridget A ^a   Tozer, Gillian M ^b,c  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b MOUNT VERNON HOSPITAL   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; COMBRETASTATIN A4 PHOSPHATE; FASUDIL; HYPOXIA INDUCIBLE FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; VASCULAR TARGETING AGENT; VASCULOTROPIN A;

AEROBIC CELL CULTURE; ANALYSIS OF VARIANCE; ARTICLE; BLADDER CARCINOMA; CANCER CELL CULTURE; COLON CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA FLANKING REGION; DOWNSTREAM PROCESSING; ENDOTHELIUM CELL; FLUORESCENCE ACTIVATED CELL SORTING; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; IMMUNOFLUORESCENCE; IN VITRO STUDY; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TISSUE CULTURE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; SIGNAL TRANSDUCTION; STILBENES; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

EID: 33845914327     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-6-280     Document Type: Article

References (30)

1. Folkman J: Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002, 29(6 Suppl 16):15-8.
2. Tozer GM, Kanthou C, Baguley BC: Disrupting tumour blood vessels. Nature Reviews 2005, 5:423-435.
3. Anderson HL, Yap JT, Miller MP, Robbins A, Jones T, Price PM: Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J Clin Oncol 2003, 21(15):2823-30.
4. Galbraith SM, Maxwell RJ, Lodge MA, Tozer GM, Wilson J, Taylor NJ, Stirling JJ, Sena L, Padhani AR, Rustin GJ: Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 2003, 21(15):2831-42.
5. Rustin GJ, Galbraith SM, Anderson H, Stratford M, Folkes LK, Sena L, Gumbrell L, Price PM: Phase I clinical trial of weeldy combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 2003, 21(15):2815-22.
6. Young SL, Chaplin DJ: Combretastatin A4 phosphate: background and current clinical status. Expert Opin Invest Drugs 2004, 13:1171-1182.
7. Pettit GR, Rhodes MR: Antineoplastic agents 389. New syntheses of the combretastatin A-4 prodrug. Anticancer Drug Des 1998, 13(3):183-91.
8. Galbraith SM, Chaplin DJ, Lee F, Stratford MR, Locke RJ, Vojnovic B, Tozer GM: Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res 2001, 21(1A):93-102.
9. Kanthou C, Tozer GM: The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 2002, 99(6):2060-9.
10. Perona R, Montaner S, Saniger L, Sanchez-Perez I, Bravo R, Lacal JC: Activation of the nuclear factor-kappaB by Rho, CDC42, and Rac-1 proteins. Genes Dev 1997, 11(4):463-75.
11. Kanthou C, Greco O, Stratford A, Cook I, Knight R, Benzakour O, Tozer G: The tubulin-binding agent combretastatin A-4-phosphate arrests endotheliall cells in mitosis and induces mitotic cell death. Am J Pathol 2004, 165(4):1401-11.
12. Tozer GM, Prise VE, Wilson J, Locke RJ, Vojnovic B, Stratford MR, Dennis MF, Chaplin DJ: Combretastatatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res 1999, 59(7):1626-34.
13. Tozer GM, Prise VE, Wilson J, Cemazar M, Shan S, Dewhirst MW, Barber PR, Vojnovic B, Chaplin DJ: Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res 2001, 61(17):6413-22.
14. Horsman MR, Ehrnrooth E, Ladekari M, Overgaard J: The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors. Int J Radiat Oncol Biol Phys 1998, 42(4):895-8.
15. El-Emir E, Boxer GM, Petrie IA, Boden RW, Dearling JL, Begent RH, Pedley RB: Tumour parameters affected by combretastatin A-4 phosphate therapy in a human colorectal xenograft model in nude mice. Eur J Cancer 2005, 41(5):799-806.
16. Dachs GU, Tozer GM: Hypoxia modulated gene expression: angiogenesis, metastasis and therapeutic exploitation. Eur J Cancer 2000, 36(13 Spec No): 1649-60.
17. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ: Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 1997, 57(10):1829-34.
18. Pugh CW, Ratcliffe PJ: The von Hippel-Lindau tumor suppressor, hypoida-inducible factor-1 (HIF-1) degradation, and cancer pathogenesis. Semin Cancer Biol 2003, 13(1):83-9.
19. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW: Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res 1999, 59(22):5830-5.
20. Sheta EA, Trout H, Gildea JJ, Harding MA, Theodorescu D: Cell density mediated pericellular hypoxia leads to induction of HIF-1alpha via nitric oxide and Ras/MAP kinase mediated signaling pathways. Oncogene 2001, 20(52):7624-34.
21. Wang GL, Semenza GL: Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction. Blood 1993, 82(12):3610-5.
22. Tozer GM, Kanthou C, Parkins CS, Hill SA: The biology of the combretastatins as tumour vascular targeting agents. Int J Exp Pathol 2002, 83(1):21-38.
23. Kallio PJ, Okamoto K, O'Brien S, Carrero P, Makino Y, Tanaka H, Poellinger L: Signal transduction in hypoxic cells: Inducible nuclear translocation and recruitment of the CBP/p300 coactivator by the hypoxia-inducible factor-1α EMBO J 1998, 17(22):6573-86.
24. Stevenson JP, Rosen M, Sun W, Gallagher M, Haller DG, Vaughn D, Giantonio B, Zimmer R, Petros WP, Stratford M, Chaplin D, Young SL, et al.: Phase I trial of the antivascular agent combretastatin A-4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 2003, 21(23):4428-38.
25. Tian H, McKnight SL, Russell DW: Endothelial PAS domain protein I (EPASI), a transcription factor selectively expressed in endothelial cells. Genes Dev 1997, 11(1):72-82.
26. Sowter HM, Raval RR, Moore JW, Ratcliffe PJ, Harris AL: Predominant role of hypoxia-inducible transcription factor (Hif)1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia. Cancer Res 2003, 63(19):6130-4.
27. Jung YJ, Isaacs JS, Lee S, Trepel J, Neckers L: Microtubule disruption utilizes an NFκB-dependent pathway to stabilize HIF-1α protein. J Biol Chem 2003, 278(9):7445-52.
28. Anwar KN, Fazal F, Malik AB, Rahman A. RhoA/Rho-associated kinase pathway selectively regulates thrombin-induced intercellular adhesion molecule-1 expression in endothelial cells via activation of 1 kappa B kinase beta and phosphorylation of ReIA/p65. J Immunol 2004, 173(11):6965-72.
29. Sheng Y, Hua J, Pinney KG, Garner CM, Kane RR, Prezioso JA, Chaplin DJ, Edvardsen K: Combretastatin family member OX14503 induces tumor vascular collapse through the induction of endothelial apoptosis Int J Cancer 2004, 111(4):604-10.
30. Theodoropoulos VE, Lazaris ACh, Sofras F, Gerzelis I, Tsoukala V, Ghikonti I, Manikas K, Kastriotis I: Hypoxia-inducible factor I alpha expression correlates with angiogenesis and unfavorable prognosis in bladder cancer. Eur Urol 2004, 46(2):200-8.